SOUTH SAN FRANCISCO, Calif., March 20 /PRNewswire/ -- Model N, the leader in Revenue Management solutions for the life sciences industry, announced today that Actelion Pharmaceuticals U.S., Inc. , a biopharmaceutical company focused on the discovery, development, and marketing of innovative drugs for significant unmet medical needs, has selected Model N’s Government Pricing application to enhance its management of governmental regulatory compliance risk.
“Successfully and efficiently managing the challenges of governmental regulatory compliance is critical to our company’s continued growth,” said Claudia Martinez, Senior Analyst of Distribution and Reimbursement at Actelion Pharmaceuticals U.S. “Government pricing is a big part of the compliance process. Our initial deployment of Model N’s Revenue Management platform, including Medicaid Claims Processing, was core to our strategy of building an infrastructure to support growth. With the Model N platform installed, the technology and integration points for government pricing were all already in place.”
With Model N Government Pricing, Actelion has a tool to improve compliance with complex drug pricing regulations. Government Pricing ensures transparency and auditability by providing visibility into data and by tracking actions at every step in the calculation and submission process. Seamless integration with commercial pricing and contract management applications available across the Model N Revenue Management suite also allows companies to better manage the dependencies between commercial and government pricing strategies.
“We are pleased that innovative pharmaceutical companies such as Actelion continue to expand their use of Model N’s regulatory compliance applications to manage their growing businesses,” said Zack Rinat, founder and CEO of Model N. “Regulatory compliance, including government pricing, is top of mind for these innovators. Federal and state governments are introducing more -- and more complex -- programs, which require manufacturers to be able to adapt to these new programs quickly. Model N Government Pricing is designed to adjust to rapid changes in programs and pricing, enabling manufacturers to adapt instantly to maintain compliance.”
About Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion markets its products through its own subsidiaries in key markets worldwide, including the United States (South San Francisco, CA) and the European Union as well as in Canada, Australia, Japan, and Switzerland. Founded in 1997, Actelion is a leading player in innovative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion shares are traded on the Swiss Exchange (ATLN). For more information, visit www.actelion.com.
About Model N
Model N is the leader in Revenue Management solutions, offering an integrated suite of applications for pricing, contracts, compliance, rebates, fees and chargebacks optimized for the industry practices of life sciences companies. Enabling the creation of a seamless, end-to-end process from pricing through settlements payment, Model N’s uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government pricing and Sarbanes-Oxley regulations. Model N customers include Actelion Biopharmaceuticals; Boston Scientific Corporation; Bristol-Myers Squibb; GE Healthcare; Gilead Sciences; Medtronic, Inc.; Novo Nordisk Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; and Pfizer, Inc. Model N is located in South San Francisco, California. For additional information, visit www.modeln.com.
NOTE: Model N is a mark of Model N, Inc. All other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
Model N
CONTACT: Carey Godbee of B3 Communications,, +1-760-758-4406, orcgodbee@b3communications.com, for Model N
